Gruhl JD, et al. - Given nonmetastatic, primary pancreatic squamous cell carcinoma (SCC) vs adenocarcinoma (AC) is considered to carry a poor prognosis; however, this is based on limited data, and no optimal definitive treatment strategy for nonmetastatic pancreatic SCC has been defined, so, researchers examined patients with nonmetastatic pancreatic cancer who were identified from the National Cancer Database, focusing on overall survival from the time of diagnosis. Presentation with more advanced disease was evident in cases of nonmetastatic pancreatic SCC, with less frequent surgical resection or management with any definitive local therapy. In contrast, more similar behavior of AC and A-SCC (adenosquamous carcinoma) was noted and these had higher surgical resection rates and improved survival. Patients with nonmetastatic SCC of the pancreas experienced most significant survival benefit with surgical resection, less significant benefit with systemic chemotherapy, and no statistical benefit with localized radiation for any subgroup.